Apollo Hospitals Enterprise (BOM:508869) EBITDA: ₹39,866 Mil (TTM As of Mar. 2026)


BOM:508869 Apollo Hospitals Enterprise Ltd BOM:508869
92 GF Score
Price ₹8,897.35
GF Value ₹8,723.27
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Apollo Hospitals Enterprise EBITDA?

Apollo Hospitals Enterprise BOM:508869 +2.30% 92 EBITDA is ₹39,866 Mil as of Mar. 2026. GuruFocus rates BOM:508869 with a GF Score™ of 92/100 and a GF Value™ of ₹8,723.27 (Fairly Valued). The stock has 4 warning signs investors should review.

Apollo Hospitals Enterprise's EBITDA for the three months ended in Mar. 2026 was ₹10,650 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹39,866 Mil.

During the past 12 months, the average EBITDA Growth Rate of Apollo Hospitals Enterprise was 22.50% per year. During the past 3 years, the average EBITDA Growth Rate was 24.40% per year. During the past 5 years, the average EBITDA Growth Rate was 22.00% per year. During the past 10 years, the average EBITDA Growth Rate was 19.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Apollo Hospitals Enterprise was 33.60% per year. The lowest was 1.30% per year. And the median was 20.50% per year.

Apollo Hospitals Enterprise's EBITDA per Share for the three months ended in Mar. 2026 was ₹73.96. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹277.17.

During the past 12 months, the average EBITDA per Share Growth Rate of Apollo Hospitals Enterprise was 22.50% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 24.40% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 21.60% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Apollo Hospitals Enterprise was 32.20% per year. The lowest was 1.30% per year. And the median was 13.50% per year.

Apollo Hospitals Enterprise  (BOM:508869) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Apollo Hospitals Enterprise EBITDA Related Terms


Apollo Hospitals Enterprise EBITDA Historical Data

* Premium members only.

The historical data trend for Apollo Hospitals Enterprise's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollo Hospitals Enterprise EBITDA Chart

Apollo Hospitals Enterprise Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25,092.00 20,728.00 24,776.00 32,551.00 39,866.00

Apollo Hospitals Enterprise Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,413.00 9,057.00 10,021.00 10,138.00 10,650.00

BOM:508869 vs HCA, THC, DVA: EBITDA Comparison

For the Medical Care Facilities subindustry, Apollo Hospitals Enterprise's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollo Hospitals Enterprise EV-to-EBITDA vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Apollo Hospitals Enterprise's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Apollo Hospitals Enterprise's EV-to-EBITDA falls into.


BOM:508869
92GF Score
Apollo Hospitals Enterprise Ltd BOM:508869
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Apollo Hospitals Enterprise's EBITDA for the fiscal year that ended in Mar. 2026 is calculated as

Apollo Hospitals Enterprise's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Mar. 2026, Apollo Hospitals Enterprise's EBITDA was ₹39,866 Mil.

Apollo Hospitals Enterprise's EBITDA for the quarter that ended in Mar. 2026 is calculated as

Apollo Hospitals Enterprise's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2026, Apollo Hospitals Enterprise's EBITDA was ₹10,650 Mil.

EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹39,866 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of ₹39,866 Mil mean?
Apollo Hospitals Enterprise (BOM:508869) has a EBITDA of ₹39,866 Mil as of Mar. 2026. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Apollo Hospitals Enterprise.
Is Apollo Hospitals Enterprise's EBITDA too high?
Apollo Hospitals Enterprise's current EBITDA is ₹39,866 Mil. Overall, Apollo Hospitals Enterprise has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apollo Hospitals Enterprise's EBITDA compare to HCA and THC?
Apollo Hospitals Enterprise's EBITDA of ₹39,866 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Healthcare Providers & Services company?
A good EBITDA depends on the Healthcare Providers & Services industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Apollo Hospitals Enterprise. Apollo Hospitals Enterprise's current EBITDA is ₹39,866 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollo Hospitals Enterprise stock overvalued right now?
Based on GuruFocus' analysis, Apollo Hospitals Enterprise (BOM:508869) is currently considered Fairly Valued. The stock's GF Value™ is ₹8,723.27, compared to a current price of ₹8,897.35 — trading 2% above its estimated fair value. The current EBITDA is ₹39,866 Mil. Apollo Hospitals Enterprise's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Apollo Hospitals Enterprise (BOM:508869), the current EBITDA is ₹39,866 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apollo Hospitals Enterprise (BOM:508869) Overvalued in 2026?

Based on GuruFocus' analysis, Apollo Hospitals Enterprise stock appears to be overvalued. The current stock price of ₹8,897.35 is trading 2% above its estimated GF Value™ of ₹8,723.27. GuruFocus considers Apollo Hospitals Enterprise to be Fairly Valued.

Key valuation signals for BOM:508869:

  • EBITDA: ₹39,866 Mil
  • GF Value™: ₹8,723.27 vs. price of ₹8,897.35 (2% above fair value)
  • GF Score™: 92/100 with 4 warning signs

No single metric tells the full story. See the BOM:508869 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Apollo Hospitals Enterprise Business Description

Other Exchanges APOLLOHOSP:India
Address No. 8-17, Shafee Mohammed Road, Sunny Side Building, East Block, 3rd Floor, Chennai, TN, IND, 600006
Apollo Hospitals Enterprise Ltd operates a network of private hospitals in India through primary, secondary, and tertiary care facilities. The firm's tertiary care hospitals provide complex care in a variety of specialties that include cardiology, oncology, neuroscience, orthopedics, radiology, and gastroenterology. Apollo Hospitals also operates primary care and diagnostics clinics as well as telemedicine units and offers consulting, health insurance, education and training, and research services. Its reportable operating segments are; Healthcare Services (represents hospitals and hospitals services); Retail Health and Diagnostics (includes clinics and diagnostics); Digital Health and Pharmacy Distribution; and Others. Maximum revenue is generated from its Healthcare Services segment.
92GF Score

Get the complete analysis for BOM:508869

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8,897.35
Price
₹8,723.27
GF Value